Thymol improves autism-like behaviour in VPA-induced ASD rats through the Pin1/p38 MAPK pathway.

Scientists tested thymol, a natural compound found in thyme, on rats with autism-like behaviors. The treatment improved the rats' behaviors and reduced brain inflammation. Thymol worked by affecting specific brain pathways involved in inflammation and brain cell connections. While these results are promising, this research was only done in animals, so we don't know yet if thymol would be safe or effective for autistic people.

This preclinical study investigated thymol, a natural compound from thyme, in a rat model of autism spectrum disorder induced by valproic acid exposure. Researchers found that thymol treatment (30 mg/kg) improved autism-like behaviors in rats and reduced brain inflammation markers including IL-1β and TNF-α. The study identified that thymol works through the Pin1/p38 MAPK pathway, reducing inflammatory processes while improving synaptic proteins (PSD95 and synaptophysin) in the prefrontal cortex. Molecular experiments confirmed that Pin1 promotes inflammation via p38 MAPK phosphorylation.

These findings suggest thymol may have therapeutic potential for autism by targeting neuroinflammation and supporting neurodevelopment, though human studies are needed.

Provides preliminary evidence for thymol as a potential autism intervention targeting neuroinflammation. However, extensive human trials needed before clinical application. Results support investigating anti-inflammatory approaches and the Pin1/p38 MAPK pathway in autism treatment development.

Animal model only - findings may not translate to humans. Sample size not reported. Single dose tested. Limited to one autism model (VPA-induced). No long-term safety or efficacy data. Mechanism partially elucidated but requires further validation.

Inflammation plays an essential role in the pathogenesis of autism spectrum disorder (ASD). Thymol is a bioactive monoterpene isolated from Thymus vulgaris that has anti-inflammatory properties and is helpful in neurodevelopmental disorders. The purpose of this study was to investigate the effects of thymol on autism-like behaviours in rats with VPA-induced ASD and to assess the related molecular mechanisms. In the prefrontal cortex (PFC) of the valproic acid (VPA)-exposed rat model, the levels of Pin1, phosphorylated p38 MAPK, interleukin-1β (IL-1β) and tumour necrosis factor (TNF)-α, were increased, and the levels of PSD95 and synaptophysin (SYP) decreased.

After thymol treatment (30 mg/kg), the VPA-induced autism-like behaviours were alleviated. Moreover, thymol also rescued the dysregulated levels of Pin1, phosphorylated p38 MAPK, IL-1β, TNF-α, PSD95, and SYP. In addition, immunofluorescence experiments showed that thymol treatment decreased the correlation between Pin1 and phosphorylated p38 MAPK. Mechanistically, Pin1 knockdown by RNA interference confirmed that Pin1 promotes inflammation via phosphorylation of p38 MAPK in the VPA exposure rat model.

In conclusion, thymol improved autism-like behaviours in VPA-induced ASD rats by reducing inflammation and improving neurodevelopment. This effect was mediated by the Pin1/p38 MAPK pathway. These results experimentally provide the potential for thymol in new therapeutic avenues for autism.